

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,124
				Filing Date	November 17, 2006
				First Named Inventor	Tomohiko Ohta
				Art Unit	1643
				Examiner Name	A. M. Gussow
Sheet	1	of	3	Attorney Docket Number	L7350.0010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/		HASHIZUME, R. et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276:14537-14540 (2001).	
		NISHIKAWA, H. et al. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. in press [online resource] http://www.jbc.org/cgi/reprint/M308540200 (2003).	
		WU-BAER, F., LAGRAZON, K., YUAN, W., BAER, R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278: 34743-34746 (2003).	
		BAER, R. & LUDWIG, T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12: 86-91 (2002).	
		VENKITARAMAN, A. R., Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182 (2002).	
		DENG, C. X. Roles of BRCA1 in centrosome duplication. Oncogene 21: 6222-6227 (2002).	
		OKUDA, M. et al. Nucleophosin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127-140 (2000).	
		TOKUYAMA, Y. et al. Specific phosphorylation of nucleophosmin on the Thr ¹⁹⁹ by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 276: 21529-21537 (2001).	
		BRZOVIC, P.S. et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. U.S.A. 100: 5646-5651 (2003).	
/AMG/		HONDA, R., TANAKA, H., & YASUDA, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27 (1997).	

Examiner Signature	/Anne M. Gussow/	Date Considered	12/01/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/588,124

Filing Date November 17, 2006

First Named Inventor Tomohiko Ohta

Art Unit 1643

Examiner Name A. M. Gussow

Attorney Docket Number L7350.0010

Sheet

2

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/		HERSHKO, A., & CIECHANOVER, A. The ubiquitin system. Annu. Rev. Biochem. 67: 425-479 (1998).	
		PICKART, C. M. Ubiquitin enters the new millennium. Mol. Cell 8: 499-504 (2001).	
		XU, X. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3: 389-395 (1999).	
		WEAVER, Z. et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21: 5097-5107 (2002).	
		HSU, L. C. & WHITE, R. L. BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. U.S.A. 95: 12983-12988 (1998).	
		HSU, L. C., DOAN, T. P. & WHITE, R. L. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res. 61: 7713-7718 (2001).	
		ZATSEPINA, O. V. et al. The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis. J. Cell. Sci. 112: 455-466 (1999).	
		WU, M. H. & YUNG, B. Y. M. UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA. J. Biol. Chem. 277: 48234-48240 (2002).	
		TAWFIC, S., OLSON, M. O., & AHMED, K. Role of protein phosphorylation in post-translational regulation of protein B23 during programmed cell death in the prostate gland. J. Biol. Chem. 270: 21009-21015 (1995).	
/AMG/		PANG, Q. et al. Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR. J. Biol. Chem. 278: 41709-41717 (2003).	

Examiner
Signature

/Anne M. Gussow/

Date

Considered

12/01/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/588,124		
		Filing Date	November 17, 2006		
		First Named Inventor	Tomohiko Ohta		
		Art Unit	1643		
		Examiner Name	A. M. Gussow		
Sheet	3	of	3	Attorney Docket Number	L7350.0010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/		OKUWAKI, M., IWAMATSU, A., TSUJIMOTO, M., & NAGATA, K. Identification of nucleophosmin/B23, an acidic nucleolar protein, as a stimulatory factor for in vitro replication of adenovirus DNA complexed with viral basic core proteins. J. Mol. Biol. 311: 41-55 (2001).	
		OKUWAKI, M., MATSUMOTO, K., TSUJIMOTO, M., & NAGATA, K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 506: 272-276 (2001).	
		KEYOMARSI, K. et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347: 1566-1575 (2002).	
		OHTA, T., MICHEL, J. J., SCHOTTELIUS, A. J., & XIONG, Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell 3: 535-541 (1999).	
		OHTA, T., MICHEL, J. J., & XIONG, Y. Association with cullin partners protects ROC proteins from proteasome-dependent degradation. Oncogene 18: 6758-6766 (1999).	
		OHTA, T. & XIONG, Y. Phosphorylation and SKP1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases. Cancer Res. 61: 1347-1353 (2001).	
/AMG/		MAEDA, I., OHTA, T., KOIZUMI, H., FUKUDA, M. In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3. FEBS Lett. 494: 181-185 (2001).	

Examiner Signature	/Anne M. Gussow/	Date Considered	12/01/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.95. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.